Speaker Profile

M.D., Chief Medical Officer, Beam Therapeutics

Amy Simon, M.D. is Chief Medical Officer of Beam Pharmaceuticals. Dr. Simon brings has over 20 years of clinical experience, serving in roles as a physician-scientist in academia and the biotechnology industry. Dr. Simon joined Beam in March 2021 from Alnylam Pharmaceuticals, where she spent over a decade in various roles with increasing responsibility for the clinical development of RNAi-based medicines, most recently serving as vice president, clinical development. During her tenure at Alnylam, she led the successful execution of clinical programs from natural history studies to Phase 1 through Phase 4 studies, regulatory interactions with both U.S. and ex-U.S. authorities, and drug approvals in the U.S. and EU. Dr. Simon was the lead clinician developing GIVLAARI® (givosiran) for patients with acute hepatic porphyria, which was approved by the Food and Drug Administration in 2019. Prior to entering the biotech industry, Dr. Simon worked in academia at Tufts University, serving as a professor and a director of the Asthma Center in the Pulmonary and Critical Care Division at Tufts University School of Medicine and as a professor at Tufts Graduate School of Biomedical Science where her laboratory conducted basic science research on asthma. She began her career in clinical practice, training as a resident in internal medicine and as a fellow in pulmonary and critical care medicine at Tufts Medical Center.  Dr. Simon holds a B.A. in history and science from Harvard University, and an M.D. from Tufts University School of Medicine.

 Session Abstract – PMWC 2022 Silicon Valley

Track Chair:
Jane Grogan, Graphite Bio


  • Building Future Precision Care in Qatar
    Session Chair: Khalid Fakhro, Sidra Medicine
    - Barbro Friden, Sidra Medicine
    - Ziyad Hijazi, Sidra Medicine
    - Edison Liu, Jackson Labs
  • Advances in Gene & Cell Therapies
    - Peter Nell, Mammoth
    - Laura Sepp-Lorenzino, Intellia Tx
    - Amy Simon, Beam Therapeutics
    - Eric Ostertag, Poseida Therapuetics
    - Jane Grogan, Graphite Bio
  • Translating CGT to the Clinic
    Session Chair: Nicole K. Paulk, UCSF
    - Matthew Porteus, Stanford
    - Eric Crombez, Ultragenyx Gene Therapy
    - Peter Francis, 4D Molecular Therapeutics
    - Erandi De Silva, Forge Biologics
    - Patrice Hugo, Q2 Solutions
  • Bioethics & Ethical Implications in Cell and Gene Therapies
    Session Chair: Ilana Yurkiewicz, Stanford University
  • Past, Present and Future of CRISPR Where will CRISPR Take Us and How is the Technology Evolving to Realize its Full Potential
    Session Chair: Janice Chen, Mammoth
    - Fyodor Urnov, UC Berkeley
    - Kiana Aran, Cardea Bio
    - Laura Sepp-Lorenzino, Intellia Tx